E
Escient Pharmaceuticals
A privately held biotechnology company
About Escient Pharmaceuticals
Escient Pharmaceuticals is a biotech startup that operates in the healthcare sector, specifically in the development of innovative therapeutic solutions. The company uses advanced medicinal chemistry and biological tools to create targeted small molecule therapeutics, which are essentially small molecules that can modulate the function of a specific target, such as a protein, in the body. These therapeutics have the potential to become unique treatment options for a wide range of diseases.
Escient's primary focus is on a new class of cell surface receptors called Mas-related G protein-coupled receptors (MRGPRs). These receptors are involved in various physiological and pathological processes, and by targeting them, Escient aims to develop treatments for diseases that currently have insufficient or nonexistent solutions.
The company's lead programs are EP262 and EP547, which are being evaluated for use in chronic urticaria (a type of skin rash) and other mast cell mediated disorders, and cholestatic pruritus (itching caused by bile flow obstruction), respectively.
Escient's business model revolves around the research, development, and eventual commercialization of these novel therapeutics. The company's revenue is expected to come from the sales of these drugs once they have been approved for use in the market.
The company prides itself on its culture of innovation, collaboration, transparency, mutual respect, and integrity, and sees itself as a pioneer in its field.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2018
- Headquarters
- San Diego, United States
- Employees
- 46
- Open positions
- None listed
- Dealroom signal
- 68.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Apr 2024 | $750M | $750M | Incyte | ↗ |
| SERIES COther financing | Nov 2022 | $120M | $480M | Abingworth · The Column Group · Altitude Life Science Ventures · Redmile Group | ↗ |
Growth signals
Latest recorded traffic for Escient Pharmaceuticals is 3.7K monthly website visits, up 76.2% over the last three months. Escient Pharmaceuticals's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
The Column Group
Osage University Partners
5AM Ventures
Sanofi Ventures
Cowen Group
Redmile Group
Perceptive Advisors
Series B and later8 investors entered at this stage
Abingworth
Altitude Life Science Ventures- CICowen Healthcare Investments
NEA
PFM Health Sciences
Avego
The Eleven Fund
Forge Life Science Partners
Other known investors2 additional known investors
Incyte
Johns Hopkins University
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Escient Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Escient Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.